Skip to main content
. 2021 Dec 16;65(1):110–122. doi: 10.1097/GRF.0000000000000674

TABLE 1.

Study Findings From Single-center Centers Performing Universal SARS-CoV-2 Screening for Obstetric Hospitalizations

References Location Time Period Study, n Positivity, n (%) Proportion Asymptomatic, n (%)
Sutton et al6 New York City 3/22-4/18/20 215 33 (13.7) 29 (87.9)
Prabhu et al7 New York City 3/22-4/20/20 675 70 (10.4) 55 (78.6)
Vintzileos et al8 New York City 3/30-4/12/20 161 32 (19.9) 21 (66)
Buckley et al9 New York City 4/4-4/15/20 307 50 (16.3) 50 (100)
Blitz et al10 New York City/Long Island 4/2- 4/9/ 20 375 64 (17.1) 45 (70.3)
Campbell et al11 Southern Connecticut 4/2-4/29/20 770 30 (3.9) 22 (73.3)
Berkowitz et al12 Ohio 5/1-5/15/20 492 10 (2.0) 7 (70)
Goldfarb et al13 Boston 4/18- 5/5/20 757 20 (2.6) 9 (45)
Fassett et al14 California 4/6-5/11/20 3923 17 (0.4) 17 (100)
Yassa et al15 Turkey 4/27-5/27/20 296 23 (7.8) 12 (525)
Tanacan et al16 Turkey 4/15-6/5/20 206 3 (1.5) 3 (100)
Doria et al17 Portugal 3/25-4/15/20 103 12 (11.4) 11 (91.6)
Cardona Perez et al18 Mexico 4/22-5/25/20 240 70 (29.0) 60 (86)

The table demonstrates US and international single-center studies evaluating test results for universal SARS-CoV-2 screening for obstetric hospitalizations.

SARS-CoV-2 indicates severe acute respiratory syndrome coronavirus 2.